CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| N1048 | NCCTG | N1048 (PROSPECT**): A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision | Adult CIRB - Late Phase Emphasis | Completed |
| S0303 | SWOG | A Phase III Trial of Modified FOLFOX6 Versus CAPOX; with Bevacizumab (NSC-704865) or Placebo; as First-Line Therapy in Patients with Previously Untreated Advanced Colorectal Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| NRG-BN002 | NRG | Phase I Study Of Ipilimumab; Nivolumab; And The Combination In Patients With Newly Diagnosed Glioblastoma | Adult CIRB - Early Phase Emphasis | Completed |
| NSABP-C-08 | NSABP | A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU); Leucovorin; and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon | Adult CIRB - Late Phase Emphasis | Completed |
| AHOD1221 | COG | A Phase 1/2 Study of Brentuximab Vedotin (SGN35; IND# 117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma | Pediatric CIRB | Completed |
| AALL0433 | COG | Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies. A Groupwide Phase III Study | Pediatric CIRB | Completed |
| GOG-0218 | GOG | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865; IND #113912) Followed by Placebo; Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab; in Women With Newly Diagnosed; Previously Untreated; Stage III or IV; Epithelial Ovarian; Primary Peritoneal or Fallopian Tube Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| EA1141 | ECOG-ACRIN | Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts | Cancer Prevention and Control CIRB | Completed |
| NRG-GY008 | NRG | A Phase II Evaluation of Copanlisib (BAY 80-6946); (IND #130822); A Selective Inhibitor of PI3KCA; in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations | Adult CIRB - Late Phase Emphasis | Completed |
| ACCL0631 | COG | Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children with High Risk Acute Lymphoblastic Leukemia (ALL): A Group-wide Non-Therapeutic Study | Pediatric CIRB | Completed |